talmapimod
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Aug 12, 2002 (NCT00043732)
Timeline
Indications
Mechanism of action
- MAP kinase p38 alphaINHIBITOR
MAPK14 inhibitor
Also potent inhibitor of MAPK11
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H]1CN(Cc2ccc(F)cc2)[C@@H](C)CN1C(=O)c1cc2c(C(=O)C(=O)N(C)C)cn(C)c2cc1Cl- Mol. weight
- 513.01 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL514201 ↗
Also known as
- scio-469
- scio-469
- scio-469
- talmapimod
- talmapimod
- talmapimod
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00508768 | Phase 1 | Jul 27, 2007 | Scios |
| NCT00113893 | Phase 2 | May 1, 2005 | Scios |
| NCT00095680 | Phase 2 | Nov 1, 2004 | Scios |
| NCT00089921 | Phase 2 | Jul 1, 2004 | Scios |
| NCT00087867 | Phase 2 | Jun 1, 2004 | Scios |
| NCT00043732 | Phase 2 | Aug 12, 2002 | Scios |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Scios | For profit | 6 | 6 | 2 | 2002 |
1 organizations
Page 1 / 1